TEXAS IN PARTNERSHIP WITH GLAXOSMITHKLINE FOR $91M FACILITY

(The following is a reformatted version of a press release
issued by the Office of the Governor of Texas and received via
electronic mail. The release was confirmed by the sender.) 
Gov. Perry Announces Major Biopharmaceutical Partnership
GlaxoSmithKline, Texas A&M Partner to Create World-Class Vaccine
Facility 
March 26, 2013 
Gov. Rick Perry was joined by Texas A&M System Chancellor John
Sharp, Dr. Brett Giroir and GlaxoSmithKline (GSK) Vaccines
Senior Vice President Antoon Loomans to announce a major
partnership creating a state-of-the-art influenza-vaccine
manufacturing facility in College Station. This $91 million
facility will anchor the Texas A&M Center for Innovation in
Advanced Development and Manufacturing (CIADM), which will play
a major role in securing our country from bio-terrorism and
global pandemic through the rapid development and manufacturing
of vaccines to protect human life. 
“Over the past decade, we have invested in innovative programs
to prioritize research in our state at both our universities and
in the private sector. This combined with Texas’ workforce and
business climate have made us a leader in high-tech innovation,
research, development and commercialization,” Gov. Perry said.
“Not only will this center keep Americans safer from epidemic,
it will bring in more than $41 billion to the state over the
next 25 years and contribute to the creation of more than 6,800
jobs in Texas.” 
This announcement builds on a series of significant investments
the state has made over the last decade to elevate Texas to the
forefront of biotech research and development, beginning in
2005, with the Texas Institute for Genomic Medicine at Texas A&M
University. Later, the National Center for Therapeutics
Manufacturing was established to create a skilled bio-pharmaceutical workforce proficient in therapeutics
manufacturing. 
“We are honored to welcome GSK to Texas A&M as a key partner in
the Center for Innovation,” Chancellor Sharp said. “GSK’s
dedication to public service is well-aligned with the Texas A&M
tradition of serving the nation and defining its future through
research and scholarship. Equally important is the cultural and
philosophical match between GSK and the A&M System, as reflected
by GSK’s desire to collaborate with academia and the U.S.
government, and their ongoing commitment to helping address
global health scourges such as pandemic influenza and malaria.” 
The foundation established by these investments helped create
the infrastructure necessary for Texas A&M to be designated by
the U.S. Health and Human Services Department as one of three
centers for Innovation in Advanced Development and Manufacturing
aimed at enhancing the nation’s emergency preparedness against
emerging infectious diseases. The Texas A&M CIADM represents the
largest commitment of a global biopharmaceutical company to
partner in Texas, and is the only one of the three centers to be
led by an academic institution. 
“GSK is privileged to deepen our commitment to U.S. public
health, as part of this unprecedented public-private
collaboration to protect against pandemics and bio-threats,”
Loomans said. “In Texas A&M we have found a partner with a rich
tradition of service, and with pioneering technologies that will
benefit the entire pharmaceutical industry in making vaccines
available and accessible to all in need.” 
Office of the Governor
(512) 463-2000 
(bjh) NY 
#<873920.660640.3.4.1.0.76>#